Pooled Analysis of Ibrutinib Shows Long-Term Efficacy in CLL
John N. Allan, MD, discusses a pooled analysis of 4 clinical trials with 4-year follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia and TP53 aberration deletion 17p or a TP53 mutation.
Watch
Recent Advances and Future Directions in the Management of HER2+ Gastric Cancer
An expert in gastric cancers provides insight on the recent advances and future directions for the management of locally advanced and metastatic gastric cancers.
The DESTINY-Gastric-01 Trial
Dr John Marshall discuss the DESTINY-Gastric01 trial and the implications of the study results to clinical practice for HER2+ metastatic gastric cancer.
Second- and Later Line Treatment Options for Metastatic HER2+ Gastric Cancer
John Marshall, MD, reviews options for second- and later line therapies and considerations for treatment sequencing in patients with HER2+ gastric cancers.
Frontline Treatment in Metastatic HER2+ Gastric Cancer
Dr John Marshall discusses frontline systemic treatment options for metastatic HER2+ gastroesophageal junction cancer and gastric cancer in general.
Molecular Testing for Metastatic HER2+ Gastric Cancer
An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.
Case Presentation: Metastatic HER2+ Gastric Cancer
John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.
Adjusting Poziotinib Dosing to Reduce Toxicity for Patients With EGFR+ or HER2 exon 20–Positive NSCLC
Xiuning Le, MD, PhD, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer.
Data Leading Up to the Next MONARCH 1 Analysis in mBC
Erika P. Hamilton, MD, discusses the data leading up to the Next MONARCH 1 study of abemaciclib plus tamoxifen or abemaciclib alone with metastatic breast cancer.
Clinical Pearls for Managing R/R DLBCL
John Burke, MD, provides clinical pearls in the recognition in treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Novel Therapies for R/R DLBCL
John Burke, MD, reflects on current novel therapies used in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
L-Mind Trial and Implications for R/R DLBCL
John Burke, MD, reviews the practical implications and role of tafasitamab and lenalidomide in addition to reviewing significant results from the L-MIND trial.
Second-line Treatment Recommendations for R/R DLBCL
John Burke, MD, considers factors for initiating second-line treatment in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Frontline Treatment Options for R/R DLBCL
John Burke, MD, discusses frontline treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Case Presentation: Diffuse Large B-cell Lymphoma
John Burke, MD, presents a case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Case 1: Treatment for Steroid-Refractory Acute GVHD
Experts discuss the treatment considerations for acute GVHD, the role of molecular testing, and considerations for steroid-refractory acute GVHD.
Case 1: Steroid-Refractory Acute GVHD
The experts discuss a case presentation of a 50-year-old woman with acute GVHD, risk factors for GVHD, and initial treatment options.
Comparing Tandem Stem Cell Transplant Approaches in Multiple Myeloma
Nicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.
Case 1: Initial Treatment Options for Low Risk P. Vera
Jamile Shammo, MD, reviews initial treatment options for patients with low risk polycythemia vera.
Case 1: Risk Assessment in P. Vera
Dr. Ruben Mesa and panel discuss the importance of and methods for risk assessment in patients with polycythemia vera.
Case 1: Diagnosis of P. Vera
Experts in MPN discuss diagnostic considerations for polycythemia vera.
Case 1: Hydroxyurea-Resistant Polycythemia Vera (P. Vera)
Prithviraj Bose, MD, reviews the case of a 57-year-old man diagnosed with polycythemia vera.
Case 1: High-Risk HER2+ Early-Stage Breast Cancer
Andrew Seidman, MD, reviews the case of a 45-year-old woman with HER2+ breast cancer, and the panel discusses initial treatment.
Investigating CAR T-Cell Therapy for Use in Different Disease Types
Michael Bishop, MD, discusses the investigations of and responses to chimeric antigen receptor T-cell therapy in different disease types.
Future Directions of BiTE and CAR T for mCRPC
A look toward the future development of bispecific T-cell engages (BiTEs) and CAR T-cell therapy for metastatic castration-resistant prostate cancer (mCRPC).
Promising Studies for the Future of Frontline mRCC
Toni Choueiri, MD, closes with promising new studies that will impact metastatic clear-cell renal cell carcinoma therapeutics in the years to come.
Using TKI/IO Combinations in Patients With mRCC
Both nivolumab + ipilimumab and lenvatinib + pembrolizumab TKI/IO combinations are discussed, with patient selection and appropriate use being the focus.
Dosing Strategies for Maximum Efficacy With Len + Pembro
Dosing strategies to achieve strong efficacy and ameliorate adverse events with the combination of lenvatinib + pembrolizumab in metastatic clear-cell renal cell carcinoma.
Case 3: The SOPHIA Trial
The experts describe the SOPHIA study of margetuximab in HER2+ advanced breast cancer.
Case 3: The NALA Trial
Experts have a detailed conversation on the NALA trial of neratinib and capecitabine for HER2+ metastatic breast cancer.